LeMaitre Vascular (NASDAQ:LMAT) Issues Q4 2026 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) updated its fourth quarter 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.750-0.81 for the period, compared to the consensus EPS estimate of 0.790. The company issued revenue guidance of $71.1 million-$73.1 million. LeMaitre Vascular also updated its FY 2026 guidance to 2.840-2.940 EPS.

Analyst Ratings Changes

A number of research analysts have recently issued reports on LMAT shares. Weiss Ratings cut shares of LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a report on Tuesday, June 30th. Citigroup restated a “market outperform” rating on shares of LeMaitre Vascular in a report on Tuesday, July 21st. Wells Fargo & Company decreased their price target on LeMaitre Vascular from $104.00 to $94.00 and set an “equal weight” rating for the company in a report on Wednesday. Citizens Jmp lifted their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a “market outperform” rating in a report on Wednesday, May 6th. Finally, Zacks Research downgraded shares of LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Four analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, LeMaitre Vascular presently has an average rating of “Hold” and a consensus price target of $110.60.

LeMaitre Vascular Stock Performance

LMAT stock traded down $25.92 during mid-day trading on Wednesday, hitting $79.86. The company had a trading volume of 1,149,215 shares, compared to its average volume of 261,171. The company has a debt-to-equity ratio of 0.42, a quick ratio of 12.20 and a current ratio of 14.32. The firm has a market cap of $1.82 billion, a PE ratio of 29.45, a price-to-earnings-growth ratio of 2.88 and a beta of 0.53. LeMaitre Vascular has a 12 month low of $79.39 and a 12 month high of $118.01. The stock’s fifty day moving average price is $97.41 and its two-hundred day moving average price is $100.04.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The company had revenue of $70.38 million for the quarter, compared to the consensus estimate of $71.47 million. During the same period in the prior year, the company earned $0.60 earnings per share. The firm’s revenue was up 9.6% on a year-over-year basis. On average, analysts forecast that LeMaitre Vascular will post 3 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 3rd. Stockholders of record on Thursday, August 20th will be given a dividend of $0.25 per share. This represents a $1.00 dividend on an annualized basis and a dividend yield of 1.3%. The ex-dividend date of this dividend is Thursday, August 20th. LeMaitre Vascular’s dividend payout ratio is currently 36.90%.

Insider Buying and Selling

In other LeMaitre Vascular news, Director Bridget A. Ross sold 5,044 shares of the company’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $111.10, for a total transaction of $560,388.40. Following the sale, the director directly owned 3,942 shares of the company’s stock, valued at $437,956.20. This represents a 56.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Trent G. Kamke sold 2,928 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total transaction of $313,296.00. Following the completion of the sale, the insider directly owned 3,749 shares in the company, valued at approximately $401,143. This trade represents a 43.85% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 54,453 shares of company stock valued at $5,906,174. 7.40% of the stock is owned by insiders.

More LeMaitre Vascular News

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Second-quarter revenue increased 9.6% year over year to $70.38 million, and earnings rose to $0.74 per share from $0.60 a year earlier. The company also maintained its quarterly dividend at $0.25 per share, representing an annualized yield of approximately 1.1%. LeMaitre Q2 2026 Financial Results
• Neutral Sentiment: LeMaitre’s second-quarter earnings call transcript provides additional management commentary on operating performance, business trends and the updated outlook. LeMaitre Vascular Q2 2026 Earnings Call Transcript
• Negative Sentiment: Second-quarter adjusted earnings of $0.74 per share missed the $0.81 analyst consensus, while revenue of $70.38 million fell short of the $71.47 million estimate. The earnings miss likely increased pressure on the stock despite year-over-year growth. LeMaitre Q2 Earnings and Revenues Lag Estimates
• Negative Sentiment: Management lowered its outlook relative to analyst expectations. Third-quarter EPS guidance of $0.66–$0.71 is below the $0.73 consensus, and full-year EPS guidance of $2.84–$2.94 trails the $3.00 estimate. Revenue guidance also came in below expectations for both periods.
• Negative Sentiment: Barrington Research downgraded LMAT from “outperform” to “market perform,” signaling less confidence in near-term upside.
• Negative Sentiment: Wells Fargo cut its price target from $104 to $94 and retained an “equal weight” rating. Although the revised target implies potential upside from recent levels, the reduction reinforces investor concerns following the earnings report.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Jump Financial LLC purchased a new position in LeMaitre Vascular during the second quarter valued at approximately $241,000. nVerses Capital LLC purchased a new position in shares of LeMaitre Vascular during the 4th quarter valued at $234,000. Virtu Financial LLC bought a new position in shares of LeMaitre Vascular in the third quarter worth $216,000. Van ECK Associates Corp raised its position in shares of LeMaitre Vascular by 80.9% in the fourth quarter. Van ECK Associates Corp now owns 2,082 shares of the medical instruments supplier’s stock worth $169,000 after buying an additional 931 shares in the last quarter. Finally, Strs Ohio purchased a new stake in shares of LeMaitre Vascular in the first quarter worth $168,000. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.